Table 1.

Characteristics of the study population

Characteristic	Infliximab (n = 1,060)	Adalimumab (n = 391)	p-value
Age [Mean(SD)] (in years)	34.1 (0.5)	35.2 (0.7)	0.21
Female (%)	53	56	0.31
Charlson score [Mean(SD)]	2.9	2.8	0.43
Disease duration*[Mean(SD)] (in years)	2.9 (0.1)	4.8 (0.2)	< 0.001
Type of IBD (%)			< 0.001
Crohn’s disease	68	79
Ulcerative colitis	32	21
Prior anti-TNF exposure (%)	18	49	< 0.001
Prior IBD hospitalization (%)	45	50	0.08
Prior IBD surgery (%)	7	17	< 0.001
Highest C-reactive protein [Mean(SD)] (mg/dL)+	32.0 (2.6)	22.6 (3.3)	0.03

IBD – inflammatory bowel diseases

^*Disease duration was defined as the interval between the first ICD-9 code for Crohn’s disease or ulcerative colitis and date of first codified mention of infliximab or adalimumab

⁺available within 60 days prior to initiation of biologics for 340 patients on infliximab and 144 on adalimumab (Values < 8mg/dL are considered normal)